Zanganeh Mahkam 4

4 · Summit Therapeutics Inc. · Filed Jan 6, 2025

Form 4

Period: 2025-01-02

DirectorCo-Chief Executive Officer10% Owner

Transactions

Award
Stock Option (right to buy)
2025-01-02$9.18/sh+10,724$98,446→ 10,724 total(indirect: By Spouse)
Exercise: $18.35Exp: 2035-01-02→ Common Stock (10,724 underlying)

Holdings

Common Stock
(indirect: By Spouse)
551,695,096
Warrant (right to buy)
(indirect: By Spouse)
Exercise: $1.58From: 2020-06-24Exp: 2029-12-24→ Common Stock (3,985,055 underlying)
3,985,055
Stock Option (right to buy)
(indirect: By Spouse)
Exercise: $2.64Exp: 2034-01-02→ Common Stock (74,545 underlying)
74,545
Common Stock
(indirect: By Trust)
25,457,666
Common Stock
(indirect: Immediate family member)
50,000
Common Stock
31,000
Common Stock
(indirect: By Trust)
10,199,776

Footnotes (4)

[F1]The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
[F2]The Reporting Person acquired beneficial ownership of these securities upon her marriage to the beneficial owner of the securities on December 18, 2024.
[F3]The option was granted on January 2, 2025 to the Reporting Person's spouse. The shares underlying the option shall vest in four quarterly installments, subject to continued service on each vesting date.
[F4]The option was granted on January 2, 2024 to the Reporting Person's spouse. The shares underlying the option are fully vested.

Documents

1 file